Category: Leukemia

Home / Established Year

CAR T-Cell therapy for Chronic Lymphocytic Leukemia

CAR T-Cell therapy for Chronic Lymphocytic Leukemia

Introduction Chronic lymphocytic leukemia (CLL) is a long-lasting condition where mature B lymphocytes, which have encountered antigens before, become cancerous. This leads to the buildup of malignant B cells in the blood, bone m..

How CAR T Cell therapy works in cancer patients
, , ,

A Deep Dive into CAR T Cell Therapy: How Does It Work?

Discover the science behind CAR T Cell therapy treatment in India! Explore how this revolutionary treatment transforms your immune cells into cancer fighters. Read our blog now to learn more about this miraculous therapy and how ..

CAR T-Cell Therapy In India
, , ,

Is CAR T-Cell Therapy Available In India?

Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target an..

, , ,

Olutasidenib is approved by FDA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation

Dec 2022: Olutasidenib (Rezlidhia) capsules were approved by the Food and Drug Administration (FDA) for adult patients with relapsed or resistant acute myeloid leukaemia (AML) who have a susceptible IDH1 mutation as identifie..

, ,

New dosing regimen for asparaginase erwinia chrysanthemi (recombinant) is approved by FDA

Dec 2022: A new Monday-Wednesday-Friday dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn has been approved by the Food and Drug Administration (Rylaze, Jazz Pharmaceuticals). Patients should receive 25 mg/m..

, , ,

Ivosidenib in combination with azacitidine is approved for newly diagnosed acute myeloid leukemia

June 2022: Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine has been approved by the Food and Drug Administration for newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older with..

, , , ,

Azacitidine is approved by FDA for newly diagnosed juvenile myelomonocytic leukemia

June 2022: The FDA has approved the drug azacitidine (Vidaza, Celgene Corp.) for children with newly diagnosed juvenile myelomonocytic leukaemia (JMML).The pharmacokinetics, pharmacodynamics, safety, and activity of azacitidine p..

, , , ,

Childhood leukemia and its treatment

Leukemia in childhood Leukemia is the most common cancer in children and teens, accounting for almost 1 out of 3 cancers. Most childhood leukemias are acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). Chronic leu..

, , , , ,

Rituximab plus chemotherapy is approved by FDA for pediatric cancer indications

March 2022: The Food and Drug Administration has approved rituximab (Rituxan, Genentech, Inc.) in conjunction with chemotherapy for CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma..

, , , , ,

Asciminib is approved for Philadelphia chromosome-positive chronic myeloid leukemia

Nov 2021: Asciminib (Scemblix, Novartis AG) was given accelerated approval by the Food and Drug Administration for patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) who had pr..

Newer
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy